Cholesterol drug setback casts doubt over multibillion-dollar race
CNBC
Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.
تحميل تطبيق نبأ للآندرويد مجانا
اقرأ على الموقع الرسمي
Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.
تحميل تطبيق نبأ للآندرويد مجانا